1. Home
  2. Companies
  3. PTX
  4. Material Events

Prescient Therapeutics (ASX:PTX) — Material Events

ASX:PTX · 13 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 11 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
11
Prescient Therapeutics Advances PTX-100 with EMA Orphan Drug Status and Global Trial ExpansionMedium
Prescient Therapeutics secures EMA orphan drug status for PTX-100, advances Phase 2a CTCL trial with global site expansion
30 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·85
Prescient Secures EMA Orphan Drug Status for PTX-100 in CTCLMedium
Prescient Therapeutics secures EMA Orphan Drug Designation for PTX-100 in CTCL
19 Nov 2025 ·Regulatory Announcement ·85
Prescient Therapeutics Narrows Loss, Advances PTX-100 Phase 2a with FDA Fast TrackHigh
Prescient Therapeutics narrows loss, advances PTX-100 Phase 2a trial with FDA Fast Track, raises $9.8M post-year-end
20 Aug 2025 ·Annual Report and Appendix 4E ·85
Prescient Therapeutics Secures $6.8M to Advance PTX-100 Cancer TrialsMedium
Prescient Therapeutics raises $6.8M via SPP, launches discounted placement to fund PTX-100 Phase 2 trials
29 July 2025 ·Capital Raising ·85
Prescient Therapeutics Accelerates PTX-100 Trial with FDA Fast Track and $6.8M RaiseMedium
Prescient Therapeutics secures FDA Fast Track for PTX-100, advances Phase 2a trial, raises AUD 6.8M
30 July 2025 ·Quarterly Activities Report and Appendix 4C ·85
Prescient Therapeutics Raises $9.8M, Advances PTX-100 with Promising Lymphoma DataMedium
Prescient Therapeutics raises $9.8M, advances PTX-100 Phase 2 trials with promising lymphoma data
10 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·80
Prescient Therapeutics Secures $9.8M to Propel PTX-100 Cancer Trial ProgressMedium
Prescient Therapeutics raises $9.8 million to advance PTX-100 cancer therapy clinical trials
31 July 2025 ·Capital Raising ·80
Prescient Therapeutics Gains EU Nod to Launch PTX-100 Phase 2a Trial in CTCLMedium
Prescient Therapeutics Secures EU Approval to Start PTX-100 Phase 2a Trial for CTCL
15 Dec 2025 ·Clinical Trial Announcement ·80
Prescient Therapeutics Extends $7M Share Purchase Plan to Fuel PTX-100 Phase 2 TrialMedium
Prescient Therapeutics extends Share Purchase Plan to raise $7M for PTX-100 Phase 2 development
15 July 2025 ·Capital Raising ·75
Prescient Therapeutics Advances PTX-100 Trials Amid Rising Losses and $9.85M Capital RaiseMedium
Prescient Therapeutics reports increased half-year loss, advances PTX-100 clinical trials, raises $9.85M capital
24 Feb 2026 ·Appendix 4D Half-year report ·75
Prescient Therapeutics Launches First US Site for PTX-100 Phase 2a TrialMedium
Prescient Therapeutics Opens First U.S. Site for PTX-100 Phase 2a CTCL Trial
16 July 2025 ·Clinical Trial Progress Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.

Market Mentions 2 - appeared in market wrap coverage

These are market wrap articles where Prescient Therapeutics (ASX:PTX) was mentioned. They reflect broader market coverage, not company-specific announcements.

Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026
Wrap
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026
Wrap